Safc
United States Updated 9 July 2026
Safc is an API manufacturer based in United States. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 June 2024 as NAI.
2
registered plants
2 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 28 June 2024 NAI US FDA
- 28 June 2024 NAI US FDA
- 4 November 2016 NAI US FDA
- 4 November 2016 NAI US FDA
- 16 August 2012 NAI US FDA
- 11 August 2011 NAI US FDA
- 4 November 2009 NAI US FDA
- 12 November 2008 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Madison, United States | 2131129 |
| Verona, United States | 3008305047 |
What they file, and where
| Molecule | Regulators | Docs |
| Paricalcitol | SFDA (Saudi Arabia), US FDA | 2 |
| Sodium Arsenite | US FDA | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 2 |
Comparing suppliers?
Choose your molecules and target markets. Safc comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 28 June 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates